Concepts (278)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Biomedical Research | 4 | 2023 | 400 | 1.530 |
Why?
|
| Cardiovascular Diseases | 8 | 2021 | 664 | 0.930 |
Why?
|
| Diabetes Mellitus, Type 1 | 5 | 2020 | 68 | 0.600 |
Why?
|
| Myopia | 8 | 2005 | 26 | 0.550 |
Why?
|
| Georgia | 7 | 2024 | 174 | 0.480 |
Why?
|
| Humans | 54 | 2024 | 37093 | 0.430 |
Why?
|
| Female | 39 | 2024 | 20969 | 0.410 |
Why?
|
| Eyeglasses | 7 | 2005 | 21 | 0.390 |
Why?
|
| Glaucoma, Open-Angle | 4 | 2003 | 74 | 0.380 |
Why?
|
| Visual Acuity | 8 | 2015 | 97 | 0.350 |
Why?
|
| Male | 36 | 2024 | 20025 | 0.340 |
Why?
|
| Resilience, Psychological | 2 | 2020 | 66 | 0.330 |
Why?
|
| Adult | 20 | 2024 | 11712 | 0.330 |
Why?
|
| Residence Characteristics | 3 | 2021 | 322 | 0.330 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2008 | 39 | 0.310 |
Why?
|
| Mentors | 3 | 2023 | 127 | 0.310 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2008 | 221 | 0.290 |
Why?
|
| Patient Compliance | 1 | 2008 | 212 | 0.280 |
Why?
|
| Middle Aged | 18 | 2023 | 10129 | 0.270 |
Why?
|
| Health Status Disparities | 3 | 2024 | 642 | 0.270 |
Why?
|
| Receptors, KIR | 2 | 2015 | 5 | 0.250 |
Why?
|
| Aged | 14 | 2023 | 6741 | 0.250 |
Why?
|
| Thyroidectomy | 2 | 2014 | 6 | 0.250 |
Why?
|
| Risk Assessment | 4 | 2020 | 753 | 0.240 |
Why?
|
| Glucocorticoids | 2 | 2015 | 86 | 0.240 |
Why?
|
| Killer Cells, Natural | 2 | 2015 | 92 | 0.240 |
Why?
|
| Intraocular Pressure | 4 | 2003 | 112 | 0.240 |
Why?
|
| Disease Progression | 9 | 2008 | 601 | 0.240 |
Why?
|
| Fathers | 1 | 2024 | 33 | 0.230 |
Why?
|
| Vision Tests | 1 | 2003 | 4 | 0.230 |
Why?
|
| Aged, 80 and over | 6 | 2023 | 2379 | 0.230 |
Why?
|
| Child | 15 | 2020 | 3131 | 0.230 |
Why?
|
| Adolescent | 9 | 2023 | 5363 | 0.230 |
Why?
|
| Breast Feeding | 1 | 2024 | 113 | 0.210 |
Why?
|
| Young Adult | 6 | 2024 | 4268 | 0.200 |
Why?
|
| Haplotypes | 2 | 2020 | 182 | 0.200 |
Why?
|
| Tropicamide | 1 | 2001 | 1 | 0.200 |
Why?
|
| Mydriatics | 1 | 2001 | 5 | 0.200 |
Why?
|
| Pupil | 1 | 2001 | 8 | 0.200 |
Why?
|
| Body Mass Index | 4 | 2021 | 854 | 0.200 |
Why?
|
| Diploidy | 2 | 2020 | 6 | 0.190 |
Why?
|
| Double-Blind Method | 7 | 2014 | 286 | 0.180 |
Why?
|
| Lactobacillus acidophilus | 2 | 2010 | 3 | 0.180 |
Why?
|
| Urban Health | 1 | 2020 | 95 | 0.180 |
Why?
|
| United States | 4 | 2023 | 4223 | 0.170 |
Why?
|
| Risk Factors | 9 | 2021 | 3562 | 0.170 |
Why?
|
| Risk Reduction Behavior | 1 | 2020 | 127 | 0.170 |
Why?
|
| Probiotics | 2 | 2010 | 25 | 0.170 |
Why?
|
| Convergence, Ocular | 2 | 1999 | 3 | 0.170 |
Why?
|
| Betaxolol | 3 | 2003 | 3 | 0.170 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2020 | 628 | 0.170 |
Why?
|
| Trabeculectomy | 3 | 2003 | 28 | 0.160 |
Why?
|
| Accommodation, Ocular | 5 | 2004 | 5 | 0.160 |
Why?
|
| Quality of Health Care | 1 | 2019 | 138 | 0.160 |
Why?
|
| Awareness | 1 | 2018 | 65 | 0.160 |
Why?
|
| Intention | 1 | 2018 | 94 | 0.150 |
Why?
|
| Registries | 2 | 2019 | 335 | 0.150 |
Why?
|
| Medicare | 1 | 2019 | 195 | 0.150 |
Why?
|
| Mortality | 1 | 2019 | 145 | 0.150 |
Why?
|
| Parathyroid Hormone | 2 | 2014 | 37 | 0.150 |
Why?
|
| Vulnerable Populations | 1 | 2019 | 140 | 0.150 |
Why?
|
| Social Class | 1 | 2019 | 247 | 0.150 |
Why?
|
| Attitude to Health | 1 | 2019 | 325 | 0.140 |
Why?
|
| Papillomavirus Vaccines | 1 | 2018 | 151 | 0.140 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2003 | 52 | 0.140 |
Why?
|
| Macular Edema | 1 | 2015 | 4 | 0.130 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 494 | 0.130 |
Why?
|
| Follow-Up Studies | 6 | 2020 | 974 | 0.130 |
Why?
|
| Dexamethasone | 1 | 2015 | 45 | 0.130 |
Why?
|
| Treatment Outcome | 6 | 2015 | 1369 | 0.130 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2015 | 59 | 0.130 |
Why?
|
| Lipids | 1 | 2016 | 235 | 0.130 |
Why?
|
| Hypoparathyroidism | 1 | 2014 | 1 | 0.130 |
Why?
|
| Cerebral Ventricles | 1 | 2014 | 23 | 0.120 |
Why?
|
| Hydrocephalus | 1 | 2014 | 16 | 0.120 |
Why?
|
| Granisetron | 1 | 2014 | 1 | 0.120 |
Why?
|
| Hypocalcemia | 1 | 2014 | 4 | 0.120 |
Why?
|
| Antiemetics | 1 | 2014 | 7 | 0.120 |
Why?
|
| Vomiting | 1 | 2014 | 14 | 0.120 |
Why?
|
| Gastroenteritis | 1 | 2014 | 17 | 0.120 |
Why?
|
| Diabetic Retinopathy | 1 | 2015 | 68 | 0.120 |
Why?
|
| Prednisolone | 1 | 2014 | 13 | 0.120 |
Why?
|
| Budesonide | 1 | 2014 | 5 | 0.120 |
Why?
|
| Bronchodilator Agents | 1 | 2014 | 25 | 0.120 |
Why?
|
| HIV Infections | 1 | 2008 | 2303 | 0.120 |
Why?
|
| Papillomavirus Infections | 1 | 2018 | 336 | 0.120 |
Why?
|
| Eye | 2 | 2005 | 71 | 0.120 |
Why?
|
| Prospective Studies | 5 | 2019 | 1378 | 0.120 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2013 | 3 | 0.110 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 2013 | 17 | 0.110 |
Why?
|
| Prognosis | 5 | 2020 | 739 | 0.110 |
Why?
|
| Sexual Behavior | 1 | 2018 | 609 | 0.110 |
Why?
|
| Saudi Arabia | 3 | 2020 | 6 | 0.110 |
Why?
|
| Cerebral Hemorrhage | 1 | 2014 | 103 | 0.110 |
Why?
|
| Visual Fields | 1 | 2003 | 71 | 0.110 |
Why?
|
| Refraction, Ocular | 5 | 2005 | 29 | 0.110 |
Why?
|
| Vision Disorders | 1 | 2003 | 58 | 0.110 |
Why?
|
| Parents | 1 | 2016 | 329 | 0.110 |
Why?
|
| Sex Factors | 5 | 2014 | 898 | 0.100 |
Why?
|
| Vitamin D | 1 | 2014 | 196 | 0.100 |
Why?
|
| Aging | 1 | 2016 | 664 | 0.100 |
Why?
|
| Case-Control Studies | 2 | 2020 | 1130 | 0.100 |
Why?
|
| Hunger | 1 | 2011 | 10 | 0.100 |
Why?
|
| Dietary Fiber | 1 | 2011 | 47 | 0.100 |
Why?
|
| Calcium | 1 | 2014 | 480 | 0.100 |
Why?
|
| Gene Expression | 1 | 2014 | 674 | 0.090 |
Why?
|
| Strabismus | 2 | 2004 | 17 | 0.090 |
Why?
|
| Vitreous Body | 2 | 2015 | 11 | 0.090 |
Why?
|
| Energy Intake | 1 | 2011 | 170 | 0.090 |
Why?
|
| Body Composition | 1 | 2011 | 162 | 0.090 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 2010 | 7 | 0.090 |
Why?
|
| Asthma | 1 | 2014 | 380 | 0.090 |
Why?
|
| Exotropia | 1 | 1999 | 4 | 0.090 |
Why?
|
| Anti-Bacterial Agents | 2 | 2010 | 352 | 0.090 |
Why?
|
| Bifidobacterium | 1 | 2009 | 3 | 0.090 |
Why?
|
| Common Cold | 1 | 2009 | 6 | 0.090 |
Why?
|
| Child, Preschool | 4 | 2016 | 1418 | 0.090 |
Why?
|
| Carbonic Anhydrase Inhibitors | 1 | 1999 | 7 | 0.090 |
Why?
|
| Diarrhea | 1 | 2010 | 89 | 0.090 |
Why?
|
| Dietary Supplements | 1 | 2011 | 208 | 0.080 |
Why?
|
| Body Weight | 1 | 2011 | 434 | 0.080 |
Why?
|
| Overweight | 1 | 2011 | 247 | 0.080 |
Why?
|
| Hospitals, Special | 1 | 1998 | 3 | 0.080 |
Why?
|
| Influenza, Human | 1 | 2009 | 83 | 0.080 |
Why?
|
| Optometry | 1 | 1998 | 5 | 0.080 |
Why?
|
| Prevalence | 3 | 2020 | 1455 | 0.080 |
Why?
|
| Statistics as Topic | 1 | 2008 | 117 | 0.080 |
Why?
|
| Ophthalmic Solutions | 2 | 2003 | 18 | 0.080 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2013 | 182 | 0.080 |
Why?
|
| Retrospective Studies | 4 | 2016 | 2026 | 0.070 |
Why?
|
| Blood Pressure | 2 | 2021 | 646 | 0.070 |
Why?
|
| Age Factors | 3 | 2009 | 1033 | 0.070 |
Why?
|
| Severity of Illness Index | 1 | 2008 | 610 | 0.070 |
Why?
|
| Health Care Costs | 1 | 1996 | 77 | 0.060 |
Why?
|
| Salvage Therapy | 1 | 1994 | 10 | 0.060 |
Why?
|
| Single-Blind Method | 2 | 2015 | 55 | 0.060 |
Why?
|
| Drug Therapy, Combination | 2 | 2015 | 227 | 0.060 |
Why?
|
| Hodgkin Disease | 1 | 1994 | 11 | 0.060 |
Why?
|
| Anterior Chamber | 1 | 2004 | 10 | 0.060 |
Why?
|
| Head and Neck Neoplasms | 1 | 1995 | 78 | 0.060 |
Why?
|
| Lens, Crystalline | 1 | 2004 | 13 | 0.060 |
Why?
|
| Cross-Sectional Studies | 3 | 2020 | 2721 | 0.060 |
Why?
|
| Soft Tissue Neoplasms | 2 | 1993 | 15 | 0.060 |
Why?
|
| Reproducibility of Results | 2 | 2004 | 935 | 0.060 |
Why?
|
| Predictive Value of Tests | 2 | 2014 | 400 | 0.060 |
Why?
|
| DNA, Neoplasm | 2 | 1993 | 92 | 0.050 |
Why?
|
| Laser Therapy | 2 | 2003 | 30 | 0.050 |
Why?
|
| Proportional Hazards Models | 2 | 2014 | 441 | 0.050 |
Why?
|
| Capacity Building | 1 | 2023 | 87 | 0.050 |
Why?
|
| Focus Groups | 1 | 2024 | 348 | 0.050 |
Why?
|
| Eye Color | 1 | 2001 | 3 | 0.050 |
Why?
|
| American Heart Association | 1 | 2021 | 21 | 0.050 |
Why?
|
| Censuses | 1 | 2021 | 24 | 0.050 |
Why?
|
| Technology | 1 | 2021 | 21 | 0.050 |
Why?
|
| Adenosine | 1 | 2020 | 59 | 0.050 |
Why?
|
| Health Education | 1 | 2024 | 338 | 0.050 |
Why?
|
| Community-Based Participatory Research | 1 | 2024 | 317 | 0.050 |
Why?
|
| Breast Neoplasms | 2 | 1996 | 1502 | 0.040 |
Why?
|
| Preventive Health Services | 1 | 2020 | 64 | 0.040 |
Why?
|
| Blood Glucose | 1 | 2021 | 353 | 0.040 |
Why?
|
| Cities | 1 | 2019 | 63 | 0.040 |
Why?
|
| Forecasting | 1 | 2019 | 128 | 0.040 |
Why?
|
| Pregnancy | 1 | 2024 | 1549 | 0.040 |
Why?
|
| Research Design | 1 | 2020 | 313 | 0.040 |
Why?
|
| Life Style | 1 | 2020 | 308 | 0.040 |
Why?
|
| Minority Groups | 1 | 2023 | 596 | 0.040 |
Why?
|
| Physicians | 1 | 2019 | 163 | 0.040 |
Why?
|
| Health Status | 1 | 2020 | 380 | 0.040 |
Why?
|
| Diet | 1 | 2024 | 801 | 0.040 |
Why?
|
| Florida | 1 | 2018 | 410 | 0.040 |
Why?
|
| Cholesterol, LDL | 1 | 2016 | 68 | 0.030 |
Why?
|
| Cholesterol, HDL | 1 | 2016 | 97 | 0.030 |
Why?
|
| Logistic Models | 1 | 2019 | 923 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2020 | 1067 | 0.030 |
Why?
|
| HLA-B Antigens | 1 | 2015 | 11 | 0.030 |
Why?
|
| Health Behavior | 1 | 2020 | 537 | 0.030 |
Why?
|
| Drug Implants | 1 | 2015 | 21 | 0.030 |
Why?
|
| Linkage Disequilibrium | 1 | 2015 | 85 | 0.030 |
Why?
|
| Exercise | 1 | 2021 | 613 | 0.030 |
Why?
|
| Tomography, Optical Coherence | 1 | 2015 | 31 | 0.030 |
Why?
|
| Flow Cytometry | 2 | 1993 | 399 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2015 | 114 | 0.030 |
Why?
|
| Universities | 1 | 2018 | 442 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2014 | 7 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2014 | 27 | 0.030 |
Why?
|
| Thyroid Function Tests | 1 | 2014 | 4 | 0.030 |
Why?
|
| Polymorphism, Genetic | 1 | 2015 | 191 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2015 | 161 | 0.030 |
Why?
|
| Preoperative Care | 1 | 2014 | 26 | 0.030 |
Why?
|
| Fluid Therapy | 1 | 2014 | 28 | 0.030 |
Why?
|
| Nebulizers and Vaporizers | 1 | 2014 | 19 | 0.030 |
Why?
|
| Arabs | 1 | 2014 | 13 | 0.030 |
Why?
|
| Leiomyosarcoma | 1 | 1993 | 3 | 0.030 |
Why?
|
| Fibrosarcoma | 1 | 1993 | 8 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2014 | 93 | 0.030 |
Why?
|
| Acute Disease | 1 | 2014 | 147 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2014 | 224 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2014 | 195 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2016 | 885 | 0.030 |
Why?
|
| Survival Analysis | 2 | 1995 | 325 | 0.030 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2020 | 864 | 0.030 |
Why?
|
| Leukemia, Hairy Cell | 1 | 1993 | 3 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2013 | 113 | 0.030 |
Why?
|
| Lectins | 1 | 1993 | 20 | 0.030 |
Why?
|
| Genotype | 1 | 2015 | 730 | 0.030 |
Why?
|
| Sarcoma | 1 | 1993 | 10 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2014 | 1492 | 0.030 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 1993 | 15 | 0.030 |
Why?
|
| Lactones | 1 | 1993 | 22 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2014 | 210 | 0.030 |
Why?
|
| Alleles | 1 | 2014 | 321 | 0.030 |
Why?
|
| Vitamin D Deficiency | 1 | 2014 | 105 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2014 | 550 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2003 | 148 | 0.030 |
Why?
|
| Carcinoma | 1 | 2013 | 96 | 0.030 |
Why?
|
| Cell Adhesion Molecules | 1 | 1993 | 75 | 0.030 |
Why?
|
| Emergency Service, Hospital | 1 | 2014 | 208 | 0.030 |
Why?
|
| Polysaccharides | 1 | 2011 | 58 | 0.020 |
Why?
|
| Infant | 1 | 2014 | 1046 | 0.020 |
Why?
|
| Antihypertensive Agents | 1 | 2003 | 284 | 0.020 |
Why?
|
| Placebos | 1 | 2010 | 37 | 0.020 |
Why?
|
| Philadelphia | 1 | 1999 | 15 | 0.020 |
Why?
|
| Chicago | 1 | 1999 | 30 | 0.020 |
Why?
|
| Time Factors | 1 | 2014 | 1742 | 0.020 |
Why?
|
| Regression Analysis | 2 | 1996 | 455 | 0.020 |
Why?
|
| Drug Utilization | 1 | 2009 | 29 | 0.020 |
Why?
|
| Absenteeism | 1 | 2009 | 11 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 225 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2014 | 485 | 0.020 |
Why?
|
| New York | 1 | 1998 | 71 | 0.020 |
Why?
|
| California | 1 | 1999 | 476 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2009 | 534 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2015 | 643 | 0.020 |
Why?
|
| Urban Population | 1 | 1999 | 333 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2010 | 1039 | 0.020 |
Why?
|
| Relative Value Scales | 1 | 1996 | 1 | 0.020 |
Why?
|
| Body Weights and Measures | 1 | 2005 | 22 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 1996 | 275 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 1995 | 37 | 0.020 |
Why?
|
| Incidence | 1 | 1998 | 922 | 0.020 |
Why?
|
| Work | 1 | 2004 | 6 | 0.020 |
Why?
|
| Reading | 1 | 2004 | 13 | 0.020 |
Why?
|
| Cisplatin | 1 | 1995 | 72 | 0.020 |
Why?
|
| Lomustine | 1 | 1994 | 1 | 0.020 |
Why?
|
| Dacarbazine | 1 | 1994 | 6 | 0.020 |
Why?
|
| Prednisone | 1 | 1994 | 27 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 1994 | 47 | 0.010 |
Why?
|
| Biometry | 1 | 2004 | 11 | 0.010 |
Why?
|
| Bleomycin | 1 | 1994 | 20 | 0.010 |
Why?
|
| Recurrence | 1 | 1994 | 131 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 1995 | 268 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2004 | 112 | 0.010 |
Why?
|
| Doxorubicin | 1 | 1994 | 84 | 0.010 |
Why?
|
| Anthropometry | 1 | 2004 | 97 | 0.010 |
Why?
|
| Prescriptions | 1 | 2003 | 18 | 0.010 |
Why?
|
| Cornea | 1 | 2002 | 58 | 0.010 |
Why?
|
| Age Distribution | 1 | 2002 | 225 | 0.010 |
Why?
|
| Sex Distribution | 1 | 2002 | 215 | 0.010 |
Why?
|
| Quality Assurance, Health Care | 1 | 2001 | 56 | 0.010 |
Why?
|
| Aneuploidy | 1 | 1993 | 23 | 0.010 |
Why?
|
| Pepsin A | 1 | 1993 | 3 | 0.010 |
Why?
|
| Bryostatins | 1 | 1993 | 2 | 0.010 |
Why?
|
| Pronase | 1 | 1993 | 4 | 0.010 |
Why?
|
| Antigens, Differentiation, B-Lymphocyte | 1 | 1993 | 5 | 0.010 |
Why?
|
| Ploidies | 1 | 1993 | 5 | 0.010 |
Why?
|
| Macrolides | 1 | 1993 | 11 | 0.010 |
Why?
|
| Paraffin Embedding | 1 | 1993 | 12 | 0.010 |
Why?
|
| Trypsin | 1 | 1993 | 38 | 0.010 |
Why?
|
| Acid Phosphatase | 1 | 1993 | 21 | 0.010 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 1993 | 41 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 1993 | 57 | 0.010 |
Why?
|
| Formaldehyde | 1 | 1993 | 33 | 0.010 |
Why?
|
| Cell Count | 1 | 1993 | 135 | 0.010 |
Why?
|
| Antigens, CD | 1 | 1993 | 121 | 0.010 |
Why?
|
| Protein Kinase C | 1 | 1993 | 120 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 1993 | 444 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 1993 | 502 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 1993 | 587 | 0.010 |
Why?
|